Glenmark Pharma gets tentative nod from USFDA for cancer treatment drug
PTI, Dec 1, 2020, 1:50 PM IST
New Delhi: Drug major Glenmark Pharma on Tuesday said it has received tentative approval from the US health regulator for Axitinib tablets, used in the treatment of kidney cancer. The tentatively approved product is the generic version of Inlyta tablets of PF Prism CV.
Glenmark Pharmaceuticals Inc, USA has received tentative approval by the United States Food & Drug Administration (USFDA) for Axitinib tablets in the strength of 1 mg and 5 mg, the company said in a regulatory filing.
Quoting IQVIA sales data for the 12 months ending October 2020, Glenmark Pharma said the Inlyta Tablets, 1 mg and 5 mg market achieved annual sales of approximately USD 518.8 million.
Glenmark’s current portfolio consists of 166 products authorised for distribution in the US market and 45 ANDA’s pending approval with the USFDA.
Udayavani is now on Telegram. Click here to join our channel and stay updated with the latest news.
Top News
Related Articles More
ISRO to study how crops grow in space on PSLV-C60 mission
ISRO & ESA agree to cooperate on astronaut training, mission implementation
Snatcher lands in police net in Delhi, AI tech helps reveal identity
AI Meets Health: The Rise of Smart Fitness Solutions
Power Up by Powering Down: 10 Energy-Saving Tips for Every Home
MUST WATCH
Latest Additions
PVR INOX rejigs media biz, appoints Chief Sales Officer Shalu Sabharwal as head
CPI(M) rallies behind party member on his remarks against Rahul, Priyanka
Mastermind of kidnapping gang targeting celebrities arrested after encounter in UP’s Bijnor
Neelamangala accident: Tried avoiding hitting car in front, lost control, claims truck driver
Grenade attack in Gurdaspur: Three Khalistan Zindabad Force members gunned down in encounter
Thanks for visiting Udayavani
You seem to have an Ad Blocker on.
To continue reading, please turn it off or whitelist Udayavani.